Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.37 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.36 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 4/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313959 | 0.84 | SIGMAR1 (0.51) | SIGMAR1HTR2CHTR2AHTR2BADRB1 | |
| SCHEMBL314643 | 0.84 | QDPR (0.43) | SIGMAR1HTR2CHTR2AHTR2B | |
| SCHEMBL314110 | 0.81 | OPRM1 (0.41) | AHRSLC6A2SLC6A4NPFFR1NPFFR2 | |
| SCHEMBL314098 | 0.81 | HTR2C (0.57) | SLC6A4SIGMAR1HTR2CHTR2AHTR2B | |
| SCHEMBL315774 | 0.78 | NISCH (0.38) | SLC6A2SLC6A4SIGMAR1SLC6A3 | |
| SCHEMBL23484640 | 0.76 | SUV39H2 (0.45) | AHRSLC6A4NPFFR1NPFFR2SLC6A3 | |
| SCHEMBL314497 | 0.75 | HTR7 (0.39) | HTR2CHTR2BADRB1 | |
| SCHEMBL314300 | 0.73 | NISCH (0.43) | HTR2CHTR2A | |
| SCHEMBL3385014 | 0.72 | SIGMAR1 (0.68) | AHRSIGMAR1HTR2CHTR2A | |
| SCHEMBL314449 | 0.72 | ADRB1 (0.36) | HTR2CHTR2AHTR2BADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093388-B2 | 3-aza spiro[5,5]undec-8-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2012-01-10 | — | — | US | claimed |
| EP-1899301-B1 | NOVEL 3-AZA-SPIRO[5.5]UNDEC-8-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2010-09-15 | — | — | EP | claimed |
| US-20090036477-A1 | Novel 3-Aza-Spiro[5,5]Undec-8-Ene Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | ANIONA APS (DK) | 2009-02-05 | — | — | US | claimed |
| EP-1899301-A1 | NOVEL 3-AZA-SPIROÝ5.5¨UNDEC-8-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-03-19 | — | — | EP | claimed |
| WO-2007000464-A1 | NOVEL 3-AZA-SPIRO[5.5]UNDEC-8-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-01-04 | — | — | WO | claimed |
| US-8093388-B2 | 3-aza spiro[5,5]undec-8-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2012-01-10 | — | — | US | disclosed |
| EP-1899301-B1 | NOVEL 3-AZA-SPIRO[5.5]UNDEC-8-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2010-09-15 | — | — | EP | disclosed |
| US-20090036477-A1 | Novel 3-Aza-Spiro[5,5]Undec-8-Ene Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | ANIONA APS (DK) | 2009-02-05 | — | — | US | disclosed |
| EP-1899301-A1 | NOVEL 3-AZA-SPIROÝ5.5¨UNDEC-8-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007000464-A1 | NOVEL 3-AZA-SPIRO[5.5]UNDEC-8-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036477-A1 | Novel 3-Aza-Spiro[5,5]Undec-8-Ene Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC18A3 | AHR 1326/4885SLC6A2 2/4885SLC6A4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.